(Q24241277)

1

0 references

Anna Liza Agero

2

0 references

Victoria Werth

3

0 references

Janet Segall

5

0 references

Dedee F Murrell

Cochrane Database of Systematic Reviews

6

0 references

publication date

21 January 2009

0 references

published in

0 references

cites work

Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Treatment of pemphigus vulgaris and pemphigus foliaceus: experience with 71 patients over a 20 year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

A single cycle of rituximab for the treatment of severe pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Double-blind clinical trial of 0.05% clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Current regimen of pulse therapy for pemphigus: minor modifications, improved results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Comparative study of pemphigus vulgaris and pemphigus foliaceus in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Guidelines for the management of pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

T cell control in autoimmune bullous skin disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Treatment of pemphigus: the need for more evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

The profile of fogo selvagem (endemic pemphigus foliaceus) at the University Hospital of Brasilia-Brazil. Epidemiological and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Plasmapheresis: technique and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Pemphigus and diet: does a link exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Dexamethasone pulse therapy in pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Genetic factors in pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Interventions for pemphigus vulgaris and pemphigus foliaceus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Controlled study of plasma exchange in pemphigus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

[[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Role of intramolecular epitope spreading in pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Post-IID 2008 International Meeting on autoimmune bullous diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

The treatment of Brazilian pemphigus foliaceus (fogo selvagem)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Pemphigus therapy with oral prednisolone regimens. A 5-year study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Treatment of oral pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Pemphigus: analysis of 1209 cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Healing effect of Pilocarpine gel 4% on skin lesions of pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

Gold: an old drug still working in refractory pemphigus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006263.PUB2

7 January 2021

10.1002/14651858.CD006263.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19160272

1 reference

Consolidated OpenCitations Corpus – April 2017